Avalyn Pharma Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Avalyn Pharma Inc.
- Former names
- Genoa Pharmaceuticals, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AVLN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001540171
- EIN
- 45-2463191
Board of directors
-
David Matthew Friedman · DirectorSince 2026
-
Erin Lavelle · DirectorSince 2026
-
Heather D. Turner · DirectorSince 2026
-
Jill Carroll · DirectorSince 2026
-
Jon Congleton · DirectorSince 2026
-
Kate Haviland · DirectorSince 2026
-
Lyn Baranowski · Director · Chief Executive OfficerSince 2026
-
Robert J. Meyer · DirectorSince 2026
Chief executives
Lyn Baranowski
· Chief Executive Officer
Since April 2026
Board connections
5 of this board's directors also sit on 9 other boards.
- via David Matthew Friedman
- via Kate Haviland
- via Kate Haviland
- via Jon Congleton
- via Erin Lavelle
- via Heather D. Turner
- via Jon Congleton
- via Erin Lavelle
- via David Matthew Friedman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $24,999,984
- 4 purchases by 3 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 1, 2026 | Novo Holdings A/S 10% owner | Derivative conversion | +3,327,734 | — | — |
| May 1, 2026 | FMR LLC 10% owner, See Remark 1 | Derivative conversion | +727,585 | — | — |
| May 1, 2026 | Jill Carroll Director | Derivative conversion | +1,419,298 | — | — |
| May 1, 2026 | Simeon George 10% owner | Derivative conversion | +1,419,298 | — | — |
| May 1, 2026 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 10% owner | Derivative conversion | +1,275,486 | — | — |
| May 1, 2026 | Novo Holdings A/S 10% owner | Open-market purchase | +555,555 | $18.00 | $9,999,990 |
| May 1, 2026 | FMR LLC 10% owner, See Remark 1 | Derivative conversion | +80,291 | — | — |
| May 1, 2026 | Jill Carroll Director | Derivative conversion | +489,486 | — | — |
| May 1, 2026 | Simeon George 10% owner | Derivative conversion | +489,486 | — | — |
| May 1, 2026 | FMR LLC 10% owner, See Remark 1 | Derivative conversion | +872,868 | — | — |
| May 1, 2026 | Jill Carroll Director | Open-market purchase | +277,778 | $18.00 | $5,000,004 |
| May 1, 2026 | Simeon George 10% owner | Open-market purchase | +277,778 | $18.00 | $5,000,004 |
| May 1, 2026 | FMR LLC 10% owner, See Remark 1 | Derivative conversion | +225,843 | — | — |
| May 1, 2026 | Simeon George 10% owner | Derivative conversion | +354,824 | — | — |
| May 1, 2026 | FMR LLC 10% owner, See Remark 1 | Derivative conversion | +377,948 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.